Navigation Links
New Comprehensive Chromosome Screening Program at Pacific Fertility Center Refines Embryo Selection, Improves Pregnancy Rates
Date:3/6/2013

San Francisco, CA (PRWEB) March 06, 2013

Comprehensive Chromosome Screening (CCS) helps reduce multiple pregnancies and the risks that accompany them. It allows selection of high-quality embryos for transfer, which not only improves implantation rates for women, but also reduces miscarriage rates.

CCS uses advanced microarray technology to test chromosomes with more than 99 percent accuracy. It allows selection of high-quality embryos for transfer, which not only improves implantation rates, but also reduces miscarriage rates. And, because CCS reliably identifies high-quality embryos, patients don't have to "hedge their bets" by having several embryos transferred at one time.

In the past, it was difficult to know which embryos were of high quality. An embryo could look fine under the microscope, but have an abnormal number of chromosomes. In fact, when researchers examine the DNA within embryos, they find that 40–90 percent of normal-appearing embryos are genetically abnormal.

Earlier types of pre-implantation genetic testing had significant shortcomings. These tests involved removal (biopsy) of cells at an early embryo stage. Sampling of single cells at an early stage was not necessarily representative of the whole embryo, and thus certain abnormalities could be missed. Early biopsy also appeared to be detrimental to the health of some embryos.

With highly sensitive CCS techniques, it is now possible to test all 23 pairs of chromosomes in an embryo at a later stage, reliably and safely learning the exact number of chromosomes. This makes it possible to identify embryos with normal genetic structure and thus select the highest-quality embryos out of a group for transfer.

How does it work at cutting-edge facilities such as the Pacific Fertility Center (PFC)? PFC reports very high pregnancy rates in its patients undergoing in vitro fertilization (IVF) using this new type of pre-implantation genetic testing.

With CCS, PFC's average implantation rates are 76 percent in women under the age of 40 and 60 percent in those older than 40. Overall, two-thirds of PFC patients receiving an embryo selected with CCS have resulted in a pregnancy confirmed by ultrasound. Improving the chances of pregnancy, reducing the risk of miscarriage, and helping to produce one healthy baby at a time, are the priorities at PFC for all patients.

About Pacific Fertility Center
Pacific Fertility Center is an international destination for male and female fertility treatment and care. It provides an extensive array of fertility treatment options ranging from intrauterine insemination (IUI), intracytoplasmic sperm injection (ICSI) and in vitro fertilization (IVF) to cutting-edge technology such as vitrification and genetic testing of embryos. For more information: http://www.pacificfertilitycenter.com.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10475037.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. EASL publishes first comprehensive literature review on the burden of liver disease in Europe
2. South Charlotte Dentistry Initiates New Emphasis on Comprehensive Dental Treatment
3. Comprehensive maternal hemorrhage protocols improve patient safety
4. Portland Employers Provide Comprehensive Financial Education to Their Employees through National Non-Profit Speakers Bureau
5. Comprehensive public health approach urged to curb gun violence in US
6. Hospital of the University of Pennsylvania receives Comprehensive Stroke Center Certification
7. InShapeMD® Opens its Second Location in North Carolina to Provide Comprehensive Wellness for the Charlotte Community
8. Santa Rosa Orthopaedics Develops Hand Center for Comprehensive Hand and Upper Extremity Treatment
9. Audiology Associates Extends Comprehensive Tinnitus Testing and Treatment Program for Mill Valley Residents
10. Center For Sight Expands Services in University Park; David Hunt, O.D., Becomes Part of Center For Sight’s Comprehensive Eye Care Team
11. First comprehensive guidelines for managing anaplastic thyroid cancer published in Thyroid journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian ... On The Brink” is the creation of published author, William Nowers. Captain Nowers ... a WWII veteran, he spent thirty years in the Navy. Following his career ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
(Date:10/12/2017)... ... ... On Saturday, October 21, the Health & Wellness Center at Florida Hospital ... for the American Heart Association Heart Walk. Teams of up to 10 people can ... their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on Saturday, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... -- Halo Labs announces the European launch of their new low ... MIBio 2017 in Cambridge, U.K on October ... biopharmaceutical samples with unprecedented speed and sensitivity while using far less ... Imaging. ... analysis system ...
(Date:9/27/2017)... 27, 2017  Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
Breaking Medicine Technology: